Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7599MR)

This product GTTS-WQ7599MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7599MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6068MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ142MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ2134MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALD-403
GTTS-WQ5211MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ133MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ9955MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ2574MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ6191MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW